Allogene Therapeutics (ALLO) incurred first-quarter 2025 loss of 28 cents per share, which matched the Zacks Consensus Estimate. In the year-ago period, the company had incurred a loss of 38 cents per share.As ALLO lacks a marketed product in its portfolio, it did not report any sales during the quarter. In the year-ago period, Allogene recorded collaboration revenues worth $0.02 million.ALLO Stock PerformanceYear to date, shares of Allogene have plunged 47% compared with the industry’s 6% decline.Image Sou ...